Expert Interview
Discussing Cytokinetics' Echocardiographic Evidence from the MAPLE-HCM Study of Aficamten in Patients with Obstructive HCM
Ticker(s): CYTK, BMYInstitution: Cedars-Sinai Medical Center
Associate Professor of Cardiology at both Cedars-Sinai and UCLA. Co-Director of the Hypertrophic Cardiomyopathy Clinic and Medical Director of the Hypertension Center at Cedars-Sinai
Manages 250+ patients with oHCM
Principal investigator in multiple clinical trials investigating novel treatment options for hypertrophic cardiomyopathy and device-based therapies for hypertension. Published over 90 manuscripts focused on hypertrophic cardiomyopathy, hypertension, and valvular heart disease.
How many patients do you manage with oHCM?
Added By: lilly_adminOn a scale from 1-10 (10 being extremely excited), where would you rate your level of excitement for Aficamten as a treatment for oHCM?
Added By: lilly_adminWhat are your thoughts about the likelihood of success for CYTK’s ACACIA trial in non-obstructive HCM given the BMY ODYSSEY data at ESC?
Added By: lilly_adminIf Aficamten becomes available and the ACACIA trial's safety and efficacy read positively, what percentage of your patients would you consider prescribing it to?
Added By: lilly_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
